GlassScriptPhysician profile
Jenna Keohane
NPI 1235675901
$711.49
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $272 · 2022: $168 · 2023: $254 · 2024: $17.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $254 · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $253.50 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $207.77 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $60.69 | 2021 | |
| Astellas Pharma US INC | $53.32 | 2023 | Myrbetriq, Veozah |
| Novo Nordisk INC | $42.28 | 2023 | Wegovy |
| Biohaven Pharmaceutical Holding Company LTD. | $41.62 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $40.66 | 2023 | Rexulti |
| Mylan Specialty L.P. | $32.26 | 2023 | Yupelri |
| Merck Sharp & Dohme LLC | $27.47 | 2023 | Verquvo, Belsomra |
| Myovant Sciences INC. | $26.27 | 2022 | |
| Gilead Sciences, INC. | $22.99 | 2022 | |
| Ascend Therapeutics US, LLC | $22.85 | 2021 | |
| Coopersurgical, INC. | $20.82 | 2021 | |
| Agile Therapeutics, INC. | $20.79 | 2021 | |
| Sumitomo Pharma America, INC. | $19.64 | 2023 | Myfembree |
| Lilly USA, LLC | $18.99 | 2023 | Emgality, Jardiance |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18.88 | 2023 | Prolia, Evenity |
| Pfizer INC. | $17.44 | 2024 | |
| Therapeuticsmd, INC. | $16.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Keohane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.